Drug Trial Radar · NCT06888492
To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)
Last checked: Nov 19, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Mar 28, 2025
Primary completion
Apr 25, 2026
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Guangzhou Jiayin Biotech LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 21, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of intravitreal injection of EXG202 in subjects with neovascular age-related Macular Degeneration (nAMD).
Conditions
- Wet Age-related Macular Degeneration (wAMD)
- Wet Age-related Macular Degeneration
Interventions
EXG202Biological
EXG202 is a gene therapy product for the treatment of wet (neovascular) age-related macular degeneration(wAMD) with a single intravitreal injection and administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability after EXG202 injectionTime frame: up to 52 weeks after treatment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hebei Eye Hospital
Xingtai, Hebei, China
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Yiwu, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.